Clopidogrel-induced thrombotic microangiopathy: a case report.

IF 1.6 4区 医学 Q3 PHARMACOLOGY & PHARMACY European journal of hospital pharmacy : science and practice Pub Date : 2024-07-04 DOI:10.1136/ejhpharm-2024-004209
Thais Lizondo López, Aina Font I Barceló, Carlos García Gutiérrez, Miquel Blasco, Ignacio Grafia, Carla Bastida, Pedro Castro-Rebollo, Dolors Soy-Muner
{"title":"Clopidogrel-induced thrombotic microangiopathy: a case report.","authors":"Thais Lizondo López, Aina Font I Barceló, Carlos García Gutiérrez, Miquel Blasco, Ignacio Grafia, Carla Bastida, Pedro Castro-Rebollo, Dolors Soy-Muner","doi":"10.1136/ejhpharm-2024-004209","DOIUrl":null,"url":null,"abstract":"<p><p>Thrombotic microangiopathy is a serious condition that can be precipitated by exposure to certain medications. Although rare, it is life threatening and requires a high index of clinical suspicion, appropriate laboratory testing and immediate cessation of the offending agent. We present a case of a 75-year-old man with a history of ischaemic heart disease treated with clopidogrel and aspirin. One month after initiating the treatment he developed microangiopathic haemolytic anaemia and thrombocytopenia. Extensive clinical and laboratory investigations suggested thrombotic microangiopathy secondary to clopidogrel. The drug was immediately discontinued and treatment with intravenous corticosteroids was started. Within a week the patient's laboratory parameters normalised, indicating successful recovery. This case highlights the role of early detection and immediate discontinuation of suspected medication in the effective management of clopidogrel-induced thrombotic microangiopathy. Healthcare professionals should consider drug-induced thrombotic microangiopathy as a possible diagnosis in patients receiving clopidogrel who present with thrombocytopenia and microangiopathic haemolytic anaemia.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of hospital pharmacy : science and practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/ejhpharm-2024-004209","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Thrombotic microangiopathy is a serious condition that can be precipitated by exposure to certain medications. Although rare, it is life threatening and requires a high index of clinical suspicion, appropriate laboratory testing and immediate cessation of the offending agent. We present a case of a 75-year-old man with a history of ischaemic heart disease treated with clopidogrel and aspirin. One month after initiating the treatment he developed microangiopathic haemolytic anaemia and thrombocytopenia. Extensive clinical and laboratory investigations suggested thrombotic microangiopathy secondary to clopidogrel. The drug was immediately discontinued and treatment with intravenous corticosteroids was started. Within a week the patient's laboratory parameters normalised, indicating successful recovery. This case highlights the role of early detection and immediate discontinuation of suspected medication in the effective management of clopidogrel-induced thrombotic microangiopathy. Healthcare professionals should consider drug-induced thrombotic microangiopathy as a possible diagnosis in patients receiving clopidogrel who present with thrombocytopenia and microangiopathic haemolytic anaemia.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
氯吡格雷诱发的血栓性微血管病:一份病例报告。
血栓性微血管病是一种严重的疾病,可因接触某些药物而诱发。这种病虽然罕见,但会危及生命,需要临床高度怀疑,进行适当的实验室检查,并立即停用违规药物。我们介绍了一例 75 岁的男性病例,他有缺血性心脏病史,曾接受氯吡格雷和阿司匹林治疗。开始治疗一个月后,他出现了微血管病性溶血性贫血和血小板减少症。广泛的临床和实验室检查表明,血栓性微血管病是继发于氯吡格雷的。医生立即停药,并开始静脉注射皮质类固醇。一周内,患者的实验室指标恢复正常,表明患者已成功康复。本病例强调了早期发现和立即停用可疑药物在有效治疗氯吡格雷诱发的血栓性微血管病中的作用。如果接受氯吡格雷治疗的患者出现血小板减少和微血管病性溶血性贫血,医护人员应将药物诱导的血栓性微血管病视为可能的诊断。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.40
自引率
5.90%
发文量
104
审稿时长
6-12 weeks
期刊介绍: European Journal of Hospital Pharmacy (EJHP) offers a high quality, peer-reviewed platform for the publication of practical and innovative research which aims to strengthen the profile and professional status of hospital pharmacists. EJHP is committed to being the leading journal on all aspects of hospital pharmacy, thereby advancing the science, practice and profession of hospital pharmacy. The journal aims to become a major source for education and inspiration to improve practice and the standard of patient care in hospitals and related institutions worldwide. EJHP is the only official journal of the European Association of Hospital Pharmacists.
期刊最新文献
Mobile pharmacies of the Ukrainian chain 'Apteka 9-1-1': access to medicines during the war in Ukraine. Integrating automated dispensing cabinets into the medication dispensing process: feedback from the practice in European hospitals. Cardiovascular events in eGFR-mutation non-small-cell lung cancer patients on osimertinib. Ceftaroline combination therapy for methicillin resistant coagulase negative Staphylococcus bacteraemia and endocarditis. Predictive performance of glomerular filtration rate equations based on cystatin C, creatinine and their combination in critically ill patients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1